Autoimmune Association Hosts a National Summit on Autoimmune Disease
Autoimmune Association will host their National Summit on Autoimmune Disease Wednesday, March 21, 2018. The National Summit is open to the public and will take place at Sidley Austin law.
A goal of the Summit is to understand why researchers are seeing certain autoimmune or related diseases in patients receiving current immunotherapies. Research panel discussion, facilitated by AARDA’s Chairman Emeritus Dr. Noel Rose, includes panelists such as Patrizio Caturegli, M.D., M.P.H. (Associate Professor of Pathology, Johns Hopkins University School of Medicine), Javid Moslehi, M. D. (Assistant Professor of Medicine at Vanderbilt School of Medicine), Michael L. Dougan, M. D., PhD (Director of the Immunotherapy Mucosal Inflammation Program, Massachusetts General Hospital), Ethan Shevach, M. D. (Cellular Immunology Section, NIH), and Jaydira Del Rivero, M.D. (Staff Clinician Pediatric Oncology Branch).
The program will also focus on important advocacy issues. Stephanie Hales (Partner, Sidley Austin LLP) will provide a congressional and regulatory outlook, including Medicare Part D. Also, Steven Taylor, Chief Executive Officer of the Sjogren’s Syndrome Foundation, will speak about “Changing the game for Sjogren’s patients: Strategies, techniques, and implications.”
Michael Ybarra, M. D., FAAEM, FACEP (Deputy Vice President of Advocacy and Strategic Alliances, PhRMA) will address emerging issues in patient access; what patients and patient advocates need to know about copay card changes, high deductible insurance plans and access to treatment. Lilly Stairs, head of Patient Advocacy with Clara Health, will speak on the topic of patient-powered advocacy.
*Videos of the day’s presentations will be released, check back soon*
Join our email list
Receive the latest blog articles, news, and more right to your inbox!
Related articles you might be interested in
Find more resources on autoimmunity
Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.